GS-073
Chronic inflammatory pain
Phase 1Active
Key Facts
About Gesynta Pharma
Gesynta Pharma is a clinical-stage biotech developing precision anti-inflammatory therapies by selectively inhibiting the mPGES-1 enzyme. Its lead asset, vipoglanstat, is in Phase 2 for endometriosis as a non-hormonal, non-opioid treatment, while a second candidate, GS-073, is poised for Phase 1 in chronic inflammatory pain. The company leverages foundational research from Karolinska Institutet and is led by a team with extensive drug development experience. Gesynta aims to address high unmet medical needs in chronic inflammatory conditions through its targeted mechanism.
View full company profile